Home » Posts tagged with » diffuse large B-cell lymphoma
Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]

November 8, 2020No CommentRead More

Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

March 3, 2020 No Comment
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]

Continue reading …

Denovo Biopharma gets FDA approval to launch phase 2b GBM trial for DB102

October 16, 2019 No Comment
Denovo Biopharma gets FDA approval to launch phase 2b GBM trial for DB102

Denovo Biopharma has secured approval from the US Food and Drug Administration (FDA) to launch its phase 2b clinical trial of DB102 in patients with newly-diagnosed glioblastoma (GBM) in combination with radiation and temozolomide. The GBM clinical study is an extension of the company’s work to identify a genetically-enriched patient population with diffuse large B-cell […]

Continue reading …